| Zeitouni, Nathalie |
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
|
|
| Active, not recruiting | 3 | 186 | US | Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Superficial Basal Cell Carcinoma | 03/24 | 02/29 | | |
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp |
|
|
| Recruiting | 3 | 165 | US | BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp | Biofrontera Bioscience GmbH | Actinic Keratoses | 09/25 | 03/26 | | |
DUSA, NCT03110159: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients |
|
|
| Completed | 1/2 | 8 | US | Levulan® Kerastick®, BLU-U Blue Light Photodynamic Therapy, blue light illumination | Medical Dermatology Specialists, DUSA Pharmaceuticals, Inc. | Skin Cancer, Non-melanoma Skin Cancer, Sun Damaged Skin, Actinic Keratosis | 02/24 | 02/24 | | |
ARTACUS, NCT04349436: A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies |
|
|
| Recruiting | 1/2 | 65 | US | RP1, intra-tumoral injection, oncolytic virus | Replimune Inc. | Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma | 09/27 | 01/28 | | |
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp |
|
|
| Completed | 1 | 100 | US | BF-200 ALA and red light LED lamp | Biofrontera Bioscience GmbH | Actinic Keratosis, Keratosis, Actinic, Keratosis | 04/23 | 04/23 | | |
